<DOC>
	<DOCNO>NCT00002430</DOCNO>
	<brief_summary>The purpose study compare two different anti-HIV drug combination , one contain nelfinavir ( NFV ) one . The best dosing schedule indinavir ( IDV ) also study .</brief_summary>
	<brief_title>A Study Compare Effectiveness Two Anti-HIV Drug Combinations</brief_title>
	<detailed_description>Patients stratify screen plasma viral RNA result ( 50,000 copies/ml v 50,000 copies/ml ) randomize 1 2 treatment arm . Group 1 receive IDV 3 time daily plus d4T/3TC twice daily . Group 2 receive IDV/NFV/d4T/3TC twice daily . Patients remain study medication 24 week see clinic every 4 week enter study . At clinic visit , blood sample take evaluate CD4 cell count plasma HIV RNA level .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIV positive . Have viral load ( level HIV blood ) least 10,000 copies/ml within 45 day study entry . Have CD4 cell count least 100 cells/mm3 within 45 day study entry . Have normal chest Xray . Have never take protease inhibitor 3TC . Are 16 year age older . Agree practice sexual abstinence use barrier method birth control ( e.g. , condom ) . Exclusion Criteria You eligible study : Have active opportunistic ( AIDSrelated ) infection cancer . Have certain type Kaposi 's sarcoma . Have hepatitis . Have chronic diarrhea . Have history certain medical condition . Are allergic study medication . Are take certain medication . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2000</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Nelfinavir</keyword>
</DOC>